

QuickView

Molins

Offering real value

Recent share price weakness stemming from the delayed introduction of a new regulatory regime for tobacco products in the US has been reversed following strong 2013 results. The shares look undervalued on the performance of the group's engineering businesses alone; the mediumterm potential from Scientific Services adds significantly to the potential.

Profits ahead of expectations

Results for the year to December 2013 show underlying pre-tax profits up by 10% to£5.4m, some £0.2m above City expectations. Progress was delivered in each division, although the product mix and uneven factory loading in Packaging Machinery contributed to a small reduction in gross and operating margins. Earlier hopes that the new tobacco products regulatory regime in the US would boost the performance of the laboratory business were not fulfilled, although the shortfall was more than balanced by progress in the machinery manufacturing businesses.

Potential in all divisions

There is a clear growth strategy for each division. In Scientific Services, the product range continues to widen at Cerulean, while the major investment in Arista Laboratories offers significant potential for when the new US regulatory regime is clarified. Organic growth remains the key in both machinery divisions; each is developing important new products, while there is added potential from the new Singapore office for Packaging Machinery. The balance sheet remains very strong; although net funds were reduced modestly to £5.2m (25p per share), a sharp reduction in the pension deficit helped lift shareholders' funds by £10.0m to £40.5m. Molins is also well able to support its acquisition ambitions.

Profit estimates raised

Estimates have been raised modestly following the results announcement, although the indicated higher tax charge means that EPS will fall in 2014. These estimates look conservative, especially if the FDA demands further testing during 2014.

Valuation: Undervalued

The prospective rating of 8.9x consensus 2014 earnings is less than half that of larger UK-based global machinery manufacturing groups (range 15.7x to 20.7x). The relative size of Molins and its high sales to the tobacco products industry account for some of the disparity, but the shares look distinctly undervalued.

Consensus estimates

Year end	Revenue (£m)	PBT (£m)	EPS (p)	DPS (p)	P/E (x)	Yield (%)
12/12	93	4.9	21.8	5.50	8.5	3.0
12/13	105	5.4	23.6	5.50	7.8	3.0
12/14e	105	5.7	20.8	5.75	8.9	3.1
12/15e	108	6.2	23.5	6.00	7.9	3.2
Source: Bloomberg						

Industrial engineering

27 February 2014



Share price graph



Share details

Code	MLIN
Listing	LSE
Shares in issue	20.2m

Business description

Molins is an international specialist technology and services group, providing high performance instrumentation, machinery and analytical services. It supplies principally to the tobacco products industry, but also to a number of FMCG industries such as pharmaceuticals, healthcare and beverages.

Bull

- Consistent and progressive recent trading record.
- Medium-term potential from FDA implementation of regulatory regime for tobacco products.
- Strong balance sheet.

Bear

- Vagaries of the capital goods cycle.
- External perception of the tobacco products industry.
- Gearing impact of pension assets and liabilities in excess of £300m.

Analysts

Nigel Harrison	+44 (0)20 3077 5700
Roger Johnston	+44 (0)20 3077 5722

industrials@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (<u>www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584</u>). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand Financial Services Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment tormission. Edison Investment Research Limited [4794244]. <u>www.edisongroup.com</u>

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publication. The securities described in the Investment Research may not be eligible for sale in all jurisdicitions or to certain categories of investors. This research is its research is distributed in the United States by Edison US to major US institutional investors only. Edison ut be treatment adviser unther Research may not be eligible for sale in all jurisdicitions or to certain categories of investors. This research is distributed in the United States by Edison US to major US institutional investors only. Edison US relies upon the "publishers" exclusion" from the definition of investment adviser under Section 202 (2)(11) of the Investment Adviser Advi C and a corresponding state securities laws. As such, Edison does not Offer or provide davice. We publish information about companies in which we believe our readers may be interested and this information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is provided by us should not be construed by any subscriber or solicetation or investment advisers or bokers, and the topic of this document. This document is provided for information purposes only and doul of the construed as an offer or solicitation for investment any perimeter any securities mentioned in this report. Paine as eristricity policy relating to personal dealing. Edison of solut on purposes only and should not be construed as a sufficient on investment advisers or bokers, any securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. Paine performance is not inceed as a sufficient or inducement to pure self who aresoers the sea

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia Wellington +64 (0)48 948 555 Level 15, 171 Featherston St Wellington 6011 New Zealand